Harrow (Nasdaq: HROW), a leading US eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies, has announced that it has entered into a US$100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. (Oaktree), a leader among global investment managers specializing in alternative investments.
Latham & Watkins LLP advises Oaktree in the financing with a deal team led by Bay Area partner Haim Zaltzman and Los Angeles/Bay Area partner Elizabeth Oh, with associate Benjamin Gelfand. Advice was also provided on corporate matters by Bay Area partner Jim Morrone; on tax matters by Bay Area partner Katharine Moir, with associate Alex Farris; on healthcare matters by Washington, D.C. partner Stuart Kurlander and Bay Area partner Betty Pang, with associate Lee Staley; on FDA matters by Washington, D.C. partner Ben Haas, with associate Seth Olson; and on other matters by Los Angeles partner Nima Mohebbi.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
